PMID: 9167190Jan 1, 1997Paper

Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells

Oncology Research
R R de JongeM Reiss

Abstract

Small-cell lung cancer (SCLC) has a significantly worse prognosis than other forms of bronchogenic carcinoma. Because transforming growth factor beta (TGF-beta) appears to play an important role in the pathogenesis of SCLC, we examined the status of the TGF-beta receptor system in a series of 11 human small-cell carcinoma cell lines. None of these cell lines expressed more than one-tenth the level of TGF-beta type II receptor (T beta R-II) gene mRNA produced by TGF-beta-sensitive normal epithelial cells. In addition, one of the cell lines expressed a second truncated T beta R-II transcript, which is predicted to encode a protein that lacks the terminal two-thirds of the serine-threonine kinase domain. No other structural alterations in the promoter or coding sequences of the T beta R-II gene were found in any of the cell lines, nor could the loss of T beta R-II mRNA expression be ascribed to de novo hypermethylation of promoter/enhancer sequences. These findings indicate that inactivation of the TGF-beta signaling pathway caused by the loss of T beta R-II gene expression is a common and, therefore, probably pathogenetically important feature of small-cell lung carcinoma.

Related Concepts

Related Feeds

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.